The Issue

Emily Walsh Martin, PhD, discusses pressing challenges currently facing CGT developers and clinicians.

Subscribe to the ASGCT Podcast Network

Find insightful intervews, riveting conversations, and incredible discoveries on the ASGCT Podcast Network.

Search “ASGCT” in your podcast app to subscribe to the ASGCT Podcast Network

Episodes

Non-AAV, Non-rare Gene Therapy with Derek Jackson

Derek Jackson, vice president of cell and gene therapy product development at Pacira BioSciences, joins The Issue to take the program in a different direction. This episode focuses on gene therapy development for a much more common disease: knee osteoarthritis.

CRISPR and Beyond with Vertex CSO David Altshuler, MD, PhD

David and Emily discuss how David and the team at Vertex think about innovation in drug development and how that impacts how they select programs and approaches for the diseases they focus on.

Gene Insertion Tech with SalioGen CEO Jason Cole

SalioGen CEO Jason Cole joins to explore the company's cutting-edge transposase-based gene insertion technology presented at the ASGCT 27th Annual Meeting.

CMC Strategy with Susan D'Costa, PhD

"Geek out" with Susan and Emily on the intricacies of defining your CMC strategy and ready yourselves for a tour-de-force of analytical and process development for viral vectors.

Regulatory Landscapes in CGT with Sabrina Mogle

Join Emily Walsh Martin, PhD for an in-depth interview with Sabrina Mogle, co-founder of RareMoon Consulting. 

AAV Immunogenicity with Federico Mingozzi, PhD

Dr. Mingozzi has done seminal work throughout his career in AAV gene therapy. Listen to him talk with Emily Walsh Martin, PhD, about his career and immunogenicity.

Gene Editing Complexities with Tom McCauley, PhD

Tom McCauley, PhD (Omega Therapeutics) joins Emily Walsh Martin, PhD to explore the next generation of molecular therapeutics on the second episode of The Issue, available now on the ASGCT Podcast Network.

The Intersection of Ethics and Gene Therapy with Dr. Ben Hurlbut

Dr. Ben Hurlbut (Arizona State University's Lincoln Center for Applied Ethics) and host Dr. Emily Walsh Martin discuss how ethics informs and impacts the field and offers a deep dive into the ethical, medical, and social considerations around germline gene editing.

The Patient Experience with Michael Storey, PharmD

Michael Storey, PharmD (Nationwide Children's Hospital), and host Emily Walsh Martin, PhD, discuss the path from patient diagnosis to therapy administration for approved gene and cell therapies including the clinical and administrative steps along the way.

2024

Breakthroughs in Muscular Dystrophy

November 19-20, 2024 | Chicago, IL

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.